ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    291-011
Previous Study | Return to List | Next Study

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02139592
Recruitment Status : Completed
First Posted : May 15, 2014
Last Update Posted : July 7, 2017
Sponsor:
Information provided by (Responsible Party):
Takeda

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 30, 2017
  Actual Study Completion Date : June 30, 2017